Skip to main content
DMAC logo

DiaMedica Therapeutics Inc.

DMACNASDAQHealthcareBiotechnology

$8.74Today:- (-)1Y +27.66%

As of Oct 26, 2026 close

Market cap
$471.04M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$5.25$10.42
Volume (live)
-
Avg. volume (3M)
220.93K

DiaMedica Therapeutics (DMAC) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), DiaMedica Therapeutics used $29.06M of cash in operating activities and spent $40.00K on capital expenditures. That left free cash flow of −$29.10M.

DiaMedica Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for DiaMedica Therapeutics Inc. (DMAC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-32.77-24.44-19.38-13.68-13.59-12.29-10.65-5.73-4.26
Depreciation & Amortization0.040.040.030.030.020.020.020.020.00
Deferred Income Tax0.000.000.000.000.000.000.000.000.08
Stock Based Compensation3.852.091.681.501.561.841.160.620.41
Change in Working Capital0.681.510.090.59-0.461.200.39-0.64-0.04
Change in Accounts Receivable-0.020.13-0.290.050.210.48-0.04-0.70-0.03
Change in Inventory0.000.000.000.000.00-0.480.00-0.37-0.76
Change in Accounts Payable0.540.010.190.23-0.590.92-0.300.370.25
Change in Other Working Capital0.08-1.12-0.160.31-0.08-0.210.730.060.49
Other Operating Activities0.08-1.27-1.150.050.220.05-0.030.04-0.09
Net Cash from Operating Activities-29.06-22.08-18.73-11.51-12.25-9.19-9.10-5.70-3.90
Investing Activities
Capital Expenditures-0.04-0.03-0.02-0.08-0.02-0.050.00-0.05-0.02
Acquisitions0.000.000.000.000.000.020.000.000.00
Purchases of Investments-59.28-50.41-69.41-45.68-69.81-16.10-12.920.000.00
Sales/Maturities of Investments57.1359.0051.1457.3049.3023.649.000.000.00
Other Investing Activities0.000.000.000.000.000.000.010.000.00
Net Cash from Investing Activities-2.198.56-18.3011.54-20.54-16.13-3.91-0.05-0.02
Financing Activities
Debt Repayment-0.01-0.01-0.01-0.01-0.010.000.000.000.00
Common Stock Issued43.2812.0036.850.0029.8528.850.0020.572.92
Other Financing Activities-0.40-0.01-0.010.000.240.050.080.650.62
Net Cash from Financing Activities43.8811.9936.84-0.0130.0928.850.0721.223.54
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.000.000.07
Net Change in Cash12.62-1.52-0.190.02-2.703.53-12.9415.47-0.38
Cash at Beginning of Period3.034.544.734.717.413.8816.821.351.74
Cash at End of Period15.653.034.544.734.717.413.8816.821.35
Free Cash Flow-29.10-22.10-18.75-11.59-12.27-9.23-9.10-5.75-3.92
Supplemental Disclosures
Income Taxes Paid-0.030.030.030.030.04---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About DiaMedica Therapeutics Cash Flow

What is DiaMedica Therapeutics's free cash flow?

DiaMedica Therapeutics had negative free cash flow of $29.10M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$29.06M minus $40.00K of capital expenditures.

How much does DiaMedica Therapeutics spend on capital expenditures?

DiaMedica Therapeutics spent $40.00K on capital expenditures in fiscal 2025, compared with $25.00K a year earlier.

Does DiaMedica Therapeutics pay dividends or buy back shares?

DiaMedica Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition